Abstract
Background & Objective:Ki-67 evaluation is an essential tool to define luminal A and B breast cancers, which is not yet systematized. The International Ki67 in Breast Cancer Working Group suggests the counting of 500 or 1000 cancer cells, which is a time-consuming process. Therefore, novel methods, such as the Eye-10 method and stepwise counting strategy, are proposed to facilitate measurement. Methods:Immunohistochemical staining of Ki67 was performed on 100 hormone-receptor-positive invasive ductal carcinoma specimens. Ki67LI was evaluated for each case, and then results were dichotomized by a cut-off point of 20%. Next, for each sample, an expert pathologist visually assessed percentages of Ki67-positive cells in 10% intervals at a glance (Eye-10 method). Finally, by using a dynamic process with rejection regions, Ki67 was defined so if the estimate belonged to the upper or lower rejection region, the Ki67 status had been determined and if the rejection region could not be reached after counting the maximum number of 400 tumor cells, the specimen was regarded as equivocal (stepwise counting strategy).Results:The comparison between Eye-10 and Ki67LI revealed almost perfect agreement (kappa coefficient =0.889), and the concordance between the stepwise counting strategy and Ki67LI was substantial (kappa coefficient =0.639).Conclusion:Both two methods left some results in the gray/intermediate zone, which is unavoidable. Both methods are much faster and simpler than evaluation of Ki67LI and are also reliable. Regarding the gray zone in both methods, further improvements in the methodology, as well as more analytical studies, are needed.
Highlights
Breast cancer is the most common malignancy in women all over the world
Gallen International Consensus Meeting, by using immunohistochemical (IHC) staining of estrogen receptors (ERs), progesterone receptors (PgRs), human epidermal growth factor receptor 2 (HER2), and Ki67, breast cancer is divided into four subtypes, i.e., Luminal A, Luminal B, Erb-B2 overexpression, and Basal-like
Among ER-positive/ HER2 negative tumors, luminal A-like tumors are defined as PgR positive and low Ki67 breast cancers with low recurrence risk based on a multigene expression assay
Summary
Breast cancer is the most common malignancy in women all over the world. Nowadays, breast cancer is not treated as a single disease but is divided into different subgroups, which each of them have a different biology, therapeutic plan, and prognosis.According to the 13th St. Among ER-positive/ HER2 negative tumors, luminal A-like tumors are defined as PgR positive and low Ki67 breast cancers with low recurrence risk based on a multigene expression assay. Luminal B-like tumors are defined as tumors with a negative or low positive reaction for PgR, high Ki67 (≥20%) index, and high recurrence risk [1]. The International Ki67 in Breast Cancer Working Group suggests the counting of 500 or 1000 cancer cells, which is a time-consuming process. Novel methods, such as the Eye-10 method and stepwise counting strategy, are proposed to facilitate measurement
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
